Zhejiang Shouxiangu Pharm Co (603896) — Working Capital to Net Assets Ratio
Zhejiang Shouxiangu Pharm Co (603896) has a Working Capital to Net Assets ratio of 42.1% as of March 2026. Working capital of CN¥963.55 Million (current assets of CN¥1.42 Billion minus current liabilities of CN¥451.51 Million) is measured against net assets of CN¥2.29 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 603896 equity financing ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Zhejiang Shouxiangu Pharm Co Working Capital to Net Assets (2012–2025)
This chart shows how Zhejiang Shouxiangu Pharm Co's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the ratio stands at 42.1%, reflecting working capital of CN¥963.55 Million against net assets of CN¥2.29 Billion CNY. Check Zhejiang Shouxiangu Pharm Co tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Zhejiang Shouxiangu Pharm Co (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Zhejiang Shouxiangu Pharm Co from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Zhejiang Shouxiangu Pharm Co market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 40.9% | CN¥924.72 Million | CN¥2.26 Billion | CN¥1.47 Billion | CN¥545.83 Million | ▼ -8.4 pp |
| 2024 | 49.4% | CN¥1.13 Billion | CN¥2.29 Billion | CN¥1.52 Billion | CN¥390.18 Million | ▼ -6.9 pp |
| 2023 | 56.3% | CN¥1.22 Billion | CN¥2.17 Billion | CN¥1.81 Billion | CN¥585.15 Million | ▼ -16.4 pp |
| 2022 | 72.6% | CN¥1.38 Billion | CN¥1.91 Billion | CN¥1.86 Billion | CN¥477.77 Million | ▲ +20.4 pp |
| 2021 | 52.2% | CN¥846.02 Million | CN¥1.62 Billion | CN¥1.05 Billion | CN¥199.28 Million | ▼ -4.9 pp |
| 2020 | 57.2% | CN¥758.11 Million | CN¥1.33 Billion | CN¥922.80 Million | CN¥164.69 Million | ▲ +18.2 pp |
| 2019 | 38.9% | CN¥456.52 Million | CN¥1.17 Billion | CN¥602.97 Million | CN¥146.45 Million | ▲ +4.8 pp |
| 2018 | 34.1% | CN¥336.25 Million | CN¥984.74 Million | CN¥532.02 Million | CN¥195.77 Million | ▼ -15.9 pp |
| 2017 | 50.1% | CN¥435.50 Million | CN¥869.75 Million | CN¥483.56 Million | CN¥48.05 Million | ▲ +49.7 pp |
| 2016 | 0.3% | CN¥1.49 Million | CN¥436.93 Million | CN¥166.86 Million | CN¥165.37 Million | ▲ +18.4 pp |
| 2015 | -18.0% | CN¥-66.51 Million | CN¥368.53 Million | CN¥159.24 Million | CN¥225.75 Million | ▼ -9.1 pp |
| 2014 | -9.0% | CN¥-28.76 Million | CN¥320.56 Million | CN¥143.17 Million | CN¥171.93 Million | ▼ -56.6 pp |
| 2013 | 47.6% | CN¥142.54 Million | CN¥299.50 Million | CN¥234.00 Million | CN¥91.46 Million | ▲ +25.8 pp |
| 2012 | 21.7% | CN¥30.09 Million | CN¥138.37 Million | CN¥145.18 Million | CN¥115.09 Million | — |